Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.41 |
| ▸ | KDM4A | O75164 | 5/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.41 |
| ▸ | HIF1AN | Q9NWT6 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 7/20 | 0.40 |
| ▸ | KDM5B | Q9UGL1 | 6/20 | 0.40 |
| ▸ | KDM5A | P29375 | 4/20 | 0.40 |
| ▸ | KDM5C | P41229 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM6B | O15054 | 3/20 | 0.40 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.40 |
| ▸ | KDM3A | Q9Y4C1 | 3/20 | 0.40 |
| ▸ | TET3 | O43151 | 2/20 | 0.40 |
| ▸ | KDM4D | Q6B0I6 | 2/20 | 0.40 |
| ▸ | TET2 | Q6N021 | 2/20 | 0.40 |
| ▸ | ALKBH5 | Q6P6C2 | 2/20 | 0.40 |
| ▸ | TET1 | Q8NFU7 | 2/20 | 0.40 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9907496 | 0.87 | CCR1 (0.47) | KDM4EKDM4AEGLN1HIF1ANL3MBTL1 | |
| SCHEMBL9907413 | 0.83 | KDM4E (0.45) | KDM4EL3MBTL1KDM4CKDM5CALDH1A1 | |
| SCHEMBL9907414 | 0.81 | TTR (0.47) | KDM4EKDM4AEGLN1HIF1ANL3MBTL1 | |
| SCHEMBL9907435 | 0.81 | KDM4E (0.41) | KDM4EKDM4AEGLN1HIF1ANL3MBTL1 | |
| SCHEMBL16517772 | 0.81 | CCR1 (0.44) | KDM4EKDM4AEGLN1HIF1ANL3MBTL1 | |
| SCHEMBL27185293 | 0.80 | CA12 (0.44) | KDM4ERAB9AKDM4CKDM5BKDM5A | |
| SCHEMBL9907439 | 0.77 | SLC6A2 (0.38) | KDM4EKDM4AEGLN1HIF1ANL3MBTL1 | |
| SCHEMBL9907512 | 0.75 | KDM4C (0.47) | KDM4EKDM4AKDM4CKDM5BKDM5A | |
| SCHEMBL9907418 | 0.75 | HTR5A (0.41) | KDM4AKDM4CKDM5BKDM5ATTR | |
| SCHEMBL9907425 | 0.75 | PTGDR2 (0.47) | TTRDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853242-B2 | Nitrogenous-ring acylguanidine derivative | ASTELLAS PHARMA INC. (JP) | 2014-10-07 | — | — | US | disclosed |
| US-8853242-B2 | Nitrogenous-ring acylguanidine derivative | ASTELLAS PHARMA INC. (JP) | 2014-10-07 | — | — | US | disclosed |
| US-8853242-B2 | Nitrogenous-ring acylguanidine derivative | ASTELLAS PHARMA INC. (JP) | 2014-10-07 | — | — | US | disclosed |
| EP-2463276-B1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2014-03-12 | — | — | EP | disclosed |
| EP-2463276-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2012-06-13 | — | — | EP | disclosed |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | KDM4E 1474/4885KDM4A 1645/4885EGLN1 4544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.